EPYSQLI vs RESTASIS MULTIDOSE

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 22, 2026·How we rate

Possible drug interaction. EPYSQLI and RESTASIS MULTIDOSE are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	EPYSQLI	RESTASIS MULTIDOSE
Rating	New	72/100
Pharmacy pays	—	~$52.85 /30
Type	RX	RX
Active ingredient	ECULIZUMAB-AAGH	CYCLOSPORINE
Manufacturer	Samsung Bioepis Co Ltd	Abbvie
Dosage forms	Injectable	Emulsion
Drug class	—	Calcineurin Inhibitor Immunosuppressant
Boxed warning	Boxed warning	None
Half-life	—	about 8.4 hours (range 5 to 18 hours)
Treats	Paroxysmal Hemoglobinuria, Myasthenia Gravis, Atypical Hemolytic Uremic Syndrome	Rheumatoid Arthritis, Focal Segmental Glomerulosclerosis, Systemic Lupus Erythematosus

epysqli restasis multidose

Rating

New

72/100

Pharmacy pays

—

~$52.85 /30

Type

Active ingredient

ECULIZUMAB-AAGH

CYCLOSPORINE

Manufacturer

Samsung Bioepis Co Ltd

Abbvie

Dosage forms

Injectable

Emulsion

Drug class

—

Calcineurin Inhibitor Immunosuppressant

Boxed warning

None

Half-life

—

about 8.4 hours (range 5 to 18 hours)

Treats

Paroxysmal Hemoglobinuria, Myasthenia Gravis, Atypical Hemolytic Uremic Syndrome

Rheumatoid Arthritis, Focal Segmental Glomerulosclerosis, Systemic Lupus Erythematosus

Frequently asked questions

What is the difference between Epysqli and Restasis Multidose?

Epysqli contains Eculizumab-Aagh, while Restasis Multidose contains Cyclosporine — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.